Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

Nat Commun. 2024 Apr 16;15(1):3284. doi: 10.1038/s41467-024-47393-3.

Abstract

The rapid evolution of SARS-CoV-2 is driven in part by a need to evade the antibody response in the face of high levels of immunity. Here, we isolate spike (S) binding monoclonal antibodies (mAbs) from vaccinees who suffered vaccine break-through infections with Omicron sub lineages BA.4 or BA.5. Twenty eight potent antibodies are isolated and characterised functionally, and in some cases structurally. Since the emergence of BA.4/5, SARS-CoV-2 has continued to accrue mutations in the S protein, to understand this we characterize neutralization of a large panel of variants and demonstrate a steady attrition of neutralization by the panel of BA.4/5 mAbs culminating in total loss of function with recent XBB.1.5.70 variants containing the so-called 'FLip' mutations at positions 455 and 456. Interestingly, activity of some mAbs is regained on the recently reported variant BA.2.86.

MeSH terms

  • Antibodies, Monoclonal*
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Humans
  • Mutation
  • Postoperative Complications*
  • SARS-CoV-2 / genetics

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral